Literature DB >> 9042583

Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats.

J Sandin1, J Georgieva, P A Schött, S O Ogren, L Terenius.   

Abstract

The newly discovered peptide nociceptin/orphanin FQ has been found to increase reactivity to pain and to influence locomotor activity after intracerebroventricular administration. This study investigated the possible role of hippocampal nociceptin/orphanin FQ in spatial learning and in spontaneous locomotion. Male rats were trained in the Morris water task after microinjection of 10 nmol nociceptin/orphanin FQ or artificial cerebrospinal fluid (as control) into the CA3 region of the dorsal hippocampus. Nociceptin/orphanin FQ was found to severely impair spatial learning without interfering with swimming performance. Intrahippocampal injection of nociceptin/ orphanin FQ markedly decreased exploratory locomotor activity including vertical movements (rearing). The data suggest that nociceptin/orphanin FQ is a potent modulator of synaptic plasticity within the hippocampus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042583     DOI: 10.1111/j.1460-9568.1997.tb01367.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  44 in total

1.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Nociceptin and the nociceptin receptor in learning and memory.

Authors:  Raül Andero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

3.  Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation.

Authors:  Benno Roozendaal; Ray Lengvilas; James L McGaugh; Olivier Civelli; Rainer K Reinscheid
Journal:  Learn Mem       Date:  2007-01-03       Impact factor: 2.460

4.  A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.

Authors:  Emilie D Smith; N Ariane Vinson; Desong Zhong; Bertold D Berrang; Jennifer L Catanzaro; James B Thomas; Hernán A Navarro; Brian P Gilmour; Jeffrey Deschamps; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

5.  Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice.

Authors:  David Bebawy; Paul Marquez; Seroje Samboul; Drupad Parikh; Abdul Hamid; Kabirullah Lutfy
Journal:  Biol Psychiatry       Date:  2010-03-31       Impact factor: 13.382

6.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Kainic acid down-regulates NOP receptor density and gene expression in human neuroblastoma SH-SY5Y cells.

Authors:  Rosalia Cannarsa; Daniela Landuzzi; Chiara Cavina; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2008-02-20       Impact factor: 3.444

9.  The role of NOP receptors in psychomotor stimulation and locomotor sensitization induced by cocaine and amphetamine in mice.

Authors:  Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

10.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.